These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31346958)

  • 1. Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer.
    Stec R; Cierniak S; Lubas A; Brzóskowska U; Syryło T; Zieliński H; Semeniuk-Wojtaś A
    Pathol Oncol Res; 2020 Apr; 26(2):1211-1219. PubMed ID: 31346958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer.
    Semeniuk-Wojtaś A; Lubas A; Cierniak S; Brzóskowska U; Syryło T; Zieliński H; Stec R
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2099-2108. PubMed ID: 32239282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
    Wolf HK; Stöber C; Hohenfellner R; Leissner J
    Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.
    El-Gendi S; Abu-Sheasha G
    Pathol Oncol Res; 2018 Apr; 24(2):309-322. PubMed ID: 28488128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
    Santos LL; Amaro T; Pereira SA; Lameiras CR; Lopes P; Bento MJ; Oliveira J; Criado B; Lopes CS
    Eur J Surg Oncol; 2003 Feb; 29(1):74-80. PubMed ID: 12559081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
    Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
    Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
    Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non-muscle invasive bladder cancer.
    Harsanyi S; Ziaran S; Bevizova K; Varchulova Novakova Z; Trebaticky B; Bujdak P; Galbavy S; Danisovic L
    Bratisl Lek Listy; 2020; 121(6):444-449. PubMed ID: 32484710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significance.
    Elkady N; Sultan M; Elkhouly E
    Indian J Pathol Microbiol; 2018; 61(4):526-531. PubMed ID: 30303142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence.
    Ziaran S; Harsanyi S; Bevizova K; Varchulova Novakova Z; Trebaticky B; Bujdak P; Galbavy S; Danisovic L
    Eur J Histochem; 2020 Mar; 64(2):. PubMed ID: 32214283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors].
    Moyano Calvo JL; Blanco Palenciano E; Beato Moreno A; Gutiérrez González M; Pérez-Lanzac Lorca A; Samaniego Torres A; Montaño JA; Fernández Castiñeiras J
    Actas Urol Esp; 2006 Oct; 30(9):871-8. PubMed ID: 17175927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.